Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of agents targeting checkpoint blockade continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging immune checkpoint inhibitors and analyzes the market trends and dynamics in a range of oncology indications.
United States, EU5, Japan.
Drug-treated patient populations by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.
10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2029, segmented by indication, combination type, and geography.
KEY DRUGS COVERED
Currently approved agents targeting PD-1, PD-L1, and CTLA-4.
DRG’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.